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Radiotherapy outcomes in laryngeal cancer – a retrospective study
Andrzej Hliniak1, Wojciech Michalski2, Zbigniew Szutkowski3, Andrzej Jarzàbski3, 
Zofia Laskus3, Zofia Frenkiel4, Antoni Osmólski4, Wojciech Rolski1
S t u d y  a i m.  To analyze the importance of pre-treatment factors (age, sex, T, N, histological differentiation, site, Hb level, per-
formance status) and to investigate the influence of cigarette smoking and pulmonary and cardiac diseases on treatment out-
comes in laryngeal cancer patients.
M a t e r i a l  a n d  m e t h o d s.  From the year 1989 until May 1995 372 consecutive patients with cancer of the larynx were ra-
dically irradiated at the 2nd Teleradiotherapy Department of The Maria Sklodowska-Curie Memorial Cancer Centre and In-
stitute of Oncology in Warsaw (MSCMCC). Pt. characteristics – 88% men; 12% women, age: 29-82 years, stages: T1-20%,
T2 – 34%, T3 – 30%, T4 – 16%, lymph node metastases: 27%.
R e s u l t s.  Complete response to treatment (CR) – 71% of cases. Loco-regional control after 2 years 52% (T1-T2 – 64%, 
T3-T4 – 40%). Early reactions: pain on swallowing, confluent mucositis and moist skin reaction in 69%, 48% and 41% of
cases, respectively. Serious late complications – 19 patients. In a majority of these cases several forms of serious damage we-
re observed. Patients with advanced disease (T3-T4) present a two times higher death risk as compared to patients in earlier
stages of the disease (T1-T2). Patients with cervical node metastases also present a two times higher death risk as compared
to N0 cases. Patients with performance status 1 or more had a respectively three or four times higher death risk than patients
with performance status – 0. No significant influence of sex, histological differentiation, site, hemoglobin level and cigarette
smoking, pulmonary and coronary diseases on treatment outcome has been found. The survival curves come down steeply three
and more years after treatment completion due to causes other than local failure. The limited number of serious early and la-
te reactions suggests the possibility of a total dose increase.
Wyniki radioterapii chorych na raka krtani – analiza retrospektywna
C e l e m pracy jest analiza wyników radykalnej radioterapii chorych na raka krtani w zale˝noÊci od typowych czynników kli-
nicznych takich jak: wiek, p∏eç, stopieƒ zaawansowania choroby, stopieƒ histopatologicznego zró˝nicowania, stopieƒ spraw-
noÊci chorego, lokalizacja nowotworu, poziom hemoglobiny we krwi oraz zbadanie znaczenia potencjalnych czynników ro-
kujàcych takich jak: intensywnoÊç palenia papierosów oraz wyst´powanie choroby wieƒcowej i stanów pogruêliczych w p∏u-
cach. Analizowano retrospektywnie informacj´ o 372 chorych leczonych w latach 1989-1995 samodzielnie i radykalnie
promieniami w Zak∏adzie Teleradioterapii II Centrum Onkologii – Instytutu w Warszawie. Charakterystyka materia∏u: 88%
m´˝czyzn, 12% kobiet, wiek: 29-82 lat, zaawansowanie: T1-20%, T2-34%, T3-30%, T4-16%, przerzuty do w´z∏ów ch∏onnych:
27%. Ca∏kowità odpowiedê na leczenie (CR) uzyskano w 71% przypadków. Wyleczenia miejscowe po 2 latach wynoszà 52%
(T1-T2 – 64%, T3-T4 – 40%). Wczesne reakcje: ból w prze∏ykaniu, zlewne zapalenie b∏ony Êluzowej i z∏uszczanie wilgotne
odnotowano odpowiednio w 69%, 48% i 41% przypadków. Ci´˝kie powik∏ania póêne stwierdzono u 19 pacjentów. Stwier-
dzono istotny wp∏yw stopnia zaawansowania klinicznego T i N oraz stopnia sprawnoÊci na ryzyko zgonu. Pacjenci w póênym
stopniu zaawansowania (T3-T4) mieli dwukrotnie wy˝sze ryzyko zgonu od pacjentów we wczesnym stopniu zaawansowania
(T1-T2). Ryzyko zgonu pacjentów z przerzutami w w´z∏ach ch∏onnych by∏o równie˝ dwukrotnie wy˝sze od odpowiedniego ry-
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Introduction
Our knowledge concerning radiotherapy of laryngeal can-
cer is mostly based on retrospective studies. The most
reliable of these are studies on patients treated at the sa-
me department, irradiated by the same team of doctors
and following the same treatment protocol. The results of
such studies can also be the starting point for prospective
and some retrospective studies [1]. In 1989 M. Wasilewski
supervised the preparation of treatment protocols of the
most frequent tumors for the 2nd Radiotherapy Depart-
ment of the MSCMCC in Warsaw in mind [2]. Until 1995
two fractionation strategies have been employed for ra-
diotherapy of laryngeal cancer – conventional and that of
concomitant boost [3]. Altogether 372 patients with can-
cer of the larynx were radically irradiated until May 1995
and have become the subject of the present analysis. What
is more, the present study also tackles the problem of ci-
garette smoking and of concomittant pulmonary and car-
diac diseases, which may affect lung ventilation capacities.
Aim of the study
To analyze the importance of pre-treatment factors such
as age, sex, T, N histological differentiation, site, Hb level,
type of treatment, performance status and the influence of
cigarette smoking on radiotherapy treatment outcomes of
laryngeal cancer patients.
Materials and
372 consecutive patients with cancer of the larynx were treated
radically between January 1989 and May 1995 at the 2nd De-
partment of Radiotherapy of the MSCMCC in Warsaw. All of
them – 327 men and 45 women were included in the analysis. Pa-
tient age ranged from 29 to 82 years, stage incl. T1, T2,T3, T4,
N1, N2, N3, M0, histopathologically confirmed as SCC of the la-
rynx. Disease stage was set basing on ENT examination, lateral
and tomography X-ray images, CT examination (if necessary),
chest X Ray and hematology. Patient characteristics are pre-
sented in Table I.
Methods
In patients with glottic cancer stage T1, T2, NO irradiation had
been performed in one stage. The entire larynx was irradiated
solely. In case of T3 NO glottic and T1, T2, T3, NO supraglottic
cancer irradiation was performed in two stages. Stage one inclu-
ded irradiation of the primary tumor and, selectively, the cervi-
cal lymphatics. Stage two included irradiation of the entire larynx
solely. The fraction dose of 2 Gy was estimated at the reference
point ICRU 50. Total dose was 66 Gy. In patients with glottic
cancer in any T stage with cervical nodes N 1,2,3 involvement ir-
radiation was applied to the entire cervical area. In both sites bo-
ost doses with 9 or 12 MeV electron beam were applied for resi-
dual tumors. Additionally, in all N+ cases, the low cervical field
was irradiated.
Fr a c t i o n a t i o n  s c h e d u l e s
Conventional irradiation: fraction dose 2 Gy, number of fractions
33, total dose 66 Gy. Total time 45 days. Concomittant boost
[2]: total dose 66.2 Gy, elective dose 50,2 Gy, 19 fractions a 1.8
Gy and 10 fractions a 1.60 Gy, boost dose 16 Gy in 10 fractions.
The overall treatment time 39- 41 days. The concomittant boost
schedule was considered as the pilot study with special attention
paid to early morbidity. There was no randomization between
the schedules.
P r e t r e a t m e n t  p r e p a r a t i o n s
Pretreatment preparations included the thermoplastic mask, lo-
calization radiograms taken on simulator, delimitation of the
tumor contour on the radiogram, central cross-section in T1 T2
glottic cancer and in T3 glottic and all supraglottic cases two
cross-section fitting to the first and second stage of the treat-
ment.
Time of irradiation was calculated by computer. The dose was
estimated in the reference point ICRU in the middle between
the two lateral portals.
S t a t i s t i c a l  m e t h o d s
Survival time, response to the treatment, time to the loco-regio-
nal recurrence and loco-regional control probability were analy-
zed. The survival time and time to loco-regional recurrence was
calculated from the beginning of irradiation to the last follow up
information or to the event – death or loco-regional recurrence
respectively. The response to treatment was defined as comple-
te tumour regression (CR) observed three months after treat-
ment completion. Time to loco-regional recurrence was availa-
ble for CR patients. Survival probability and loco-regional recur-
rence-free probability were estimated using the Kaplan-Meier
method [4]. Loco-regional control probability was obtained by
multiplication of the CR-probability and loco-regional recur-
rence free probability. The prognostic factors analysis for su-
rvival and loco-regional recurrence free probability was perfor-
med by means of Cox's proportional hazard model [5]. Analysis
of prognostic factors analysis for treatment response was perfor-
med using the logit regression model. The indicator of the treat-
ment schedule (conventional / concomitant boost) was involved
into the models. In the first step of the modeling process the ty-
pical prognostic factors: age, sex, stage, site, hemoglobin level,
performance status and histological differentiation were inclu-
ded. In the modeling process the backward selection method
on the p=0,1 level was applied. The models obtained were used
for testing the two factors: cigarette smoking intensity and respi-
ratory insufficiency. The statistical significance level was fixed as
zyka dla pacjentów w stopniu N0. Pacjenci w stopniu sprawnoÊci 1 i powy˝ej sà obcià˝eni trzy- i czterokrotnie wy˝szym ryzy-
kiem zgonu od pacjentów w stopniu sprawnoÊci 0. Nie stwierdzono statystycznie istotnego wp∏ywu: p∏ci, stopnia zró˝nicowa-
nia G, lokalizacji, poziomu hemoglobiny, intensywnoÊci palenia papierosów oraz wyst´powania choroby wieƒcowej i stanów
pogruêliczych w p∏ucach. Krzywe prze˝ycia opadajà stromo trzy i wi´cej lat po zakoƒczeniu leczenia z powodów innych ni˝ miej-
scowe niepowodzenie. Ograniczona liczba przypadków ci´˝kich wczesnych i póênych powik∏aƒ sk∏ania do rozwa˝enia mo˝-
liwoÊci podwy˝szenia dawki ca∏kowitej.
S∏owa kluczowe: rak krtani, radioterapia, analiza retrospektywna
Key words: cancer of the larynx, radiotherapy, retrospective study
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α=0.05. The definitions of the analyzed factors are presented in
Table I.
Table I. Patient characteristics
N (%) 372 (100)
or mean ± SE
T-stage
T1 74 (20)
T2 123 (34)
T3 112 (30)
T4 57 (16)
missing 6
N-stage
N- 270 (73)
N+ 100 (27)
missing 2
site
supraglottic 197 (57)
glottic 151 (43)
missing 24
hemoglobin level (Hb) 13.8 ± 0.09
missing 36
sex
female 45 (12)
male 327 (88)
age
≤55 138 (37)
(55, 70] 197 (53)
>70 37 (10)
performance status (WHO)
0 238 (64)
1 112 (30)
>1 21 (6)
missing 1
differentiation
G1 148 (41)
G2 82 (22)
G3 29 (8)
Gx 107 (29)
missing 6
respiratory insufficiency
no 311 (84)
yes (tbc, coronary disease,  hypertension) 61 (16)
smoking (cigarettes/day * years)
0 116 (31)
(0, 580] 74 (19)
(580, 875] 91 (25)
>875 91 (25)
treatment protocol
conventional 251 (68)
concomitant boost 121 (32)
Results
The overall survival and the survivals for the early (T1-T2)
and late (T3-T4) stages are presented in Figures 1 and
2. Similarly, curves for loco-regional recurrence-free pro-
bability and for loco-regional control probability are
shown on Figures: 3-4 and 5-6, respectively. The related
probability values for 2, 5 and 8 years of follow-up time
are shown in Tables II, IIIa and IIIb. In the early and late
stages the patients with metastases in the lymphatic nodes
Figure 1. Survival curve (entire group)
Figure 2. Survival curves in T1-T2 and T3-T4 stages
Figure 3. Loco-regional recurrence-free probability curve (patients
with CR)
Figure 4. Loco-regional recurrence-free probability curve in T1-T2 and
T3-T4 stages  (patiens with CR).
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(N+) made a 14% and 41% rate, respectively. CR was
observed in 265 (71%) cases.
Cox's model factors for the death risk function and
the loco-regional recurrence are presented in Table IV
and Table VI, respectively. Table V presents the parame-
ters of the logit regression model for CR. The frequency
of the early and late reactions were presented in Ta-
bles VII, VIIIa, VIIIb. The most frequent early reactions,
i.e. pain on swallowing, confluent mucositis and moist
skin reaction were recorded in 69%, 48% and 41% of
cases, respectively. Serious late complications were noted
in 19 patients. In a majority of these cases several forms of
serious damage were observed. Rescue surgery was per-
formed in 56 patients (29%) with diagnosed recurrence.
In 25 patients (7%) a second cancer was recorded du-
ring follow-up.
The prognostic value of T and N factors for survival
was confirmed (Table IV). Patients with advanced stages
of the disease (T3, T4) have a twice as high death risk as
patients in early stages (T1, T2). The death risk of pa-
tients with the N(+) feature is also about double that of
patients with N(-) feature. We also confirmed the influen-
ce of the performance status on survival. Patients with
Figure 5. Loco-regional control (entire group) Figure 6. Loco-regional control in T1-T2 and T3-T4 stages
Table IV. Cox's model factors for the death risk function
Variable β Standard error p – value Relative risk
T-stage 0.0241
T2 0.2710 0.2522 0.2825 1.3113
T3 0.5901 0.2539 0.0201 1.8042
T4 0.7607 0.2784 0.0063 2.1398
N+ 0.8136 0.1709 <0.0001 2.2560
male 0.4345 0.2627 0.0981 1.5441
age 0.0319
(55, 70] 0.1519 0.1806 0.4004 1.1640
>70 0.7307 0.2836 0.0100 2.0765
performance status (WHO) <0.0001
1 1.0732 0.1625 <0.0001 2.9247
2 1.4217 0.2976 <0.0001 4.1440
respiratory insufficiency 0.1371 0.2043 0.5023 1.1469
smoking (cigarettes/day * years) 0.6292
(0, 580] -.2652 0.2273 0.2433 0.7670
(580, 875] -.0401 0.2070 0.8462 0.9606
>875 -.1716 0.2137 0.4220 0.8423
Concomitant boost 0.0778 0.1701 0.6475 1.0809
Table II. Survival probability in T1-T2 and T3-T4 stages
Follow-up Survival probability ± standard error
(years) All patients T1-T2 T3-T4
2 0.67 ± 0.03 0.78 ± 0.03 0.55 ± 0.04
5 0.47 ±  0.03 0.60 ± 0.04 0.32 ± 0.04
8 0.37 ±  0.03 0.51 ± 0.05 0.21 ± 0.05
Table IIIa. Loco-regional recurrence-free probability in T1-T2 
and T3-T4 stages
Follow-up Probability ± standard error
(years) All patients T1-T2 T3-T4
2 0.73 ±  0.03 0.80 ± 0.03 0.67 ± 0.04
5 0.66 ± 0.03 0.76 ± 0.03 0.57 ± 0.04
8 0.62 ± 0.04 0.75 ± 0.04 0.51 ± 0.07
Table IIIb. Loco-regional control in T1-T2 and T3-T4 stages
Follow-up Probability ±  standard error
(years)
All patients T1-T2 T3-T4
2 0.52 ±  0.03 0.64 ± 0.04 0.40 ± 0.04
5 0.47 ± 0.03 0.59 ± 0.04 0.34 ± 0.04
8 0.44 ±  0.03 0.57 ± 0.04 0.27 ± 0.07
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WHO=1 or WHO=2 have a respectively three or four ti-
mes higher death risk than patients with WHO=0. We
observed no influence of sex, histological differentiation,
hemoglobin level and tumor site on survival. The negati-
ve influences of cigarette smoking and of potential re-
spiratory insufficiency were not confirmed.
The significant influence of T-stage on the treat-
ment response (CR) was confirmed (Table V). The CR
chance of patients with T4 tumours equals 33% of the
CR chance of patients with T1 tumours. The treat-
ment response analysis of patients with expected respira-
tory insufficiency indicated significantly better results
than in patients with no such anamnesis (!). The T-stage
Table V. Logit model factors for the probability of CR
Variable β Standard error p – value Odds ratio
T-stage 0,0057
T2 0.0207 0.3627 0.9551 1.0209
T3 -.5757 0.3495 0.1045 0.5623
T4 -1.1098 0.3938 0.0063 0.3296
respiratory insufficiency 0.8464 0.3850 0.0279 2.3313
smoking (cigarettes/day * years) 0.9521
(0, 580] 0.0983 0.3437 0.7749 1.1033
(580, 875] 0.0360 0.3269 0.9124 1.0366
>875 -.1062 0.3286 0.7465 0.8992
Concomitant boost 0.3040 0.2679 0.2564 1.3553
Constant 0.3969 0.3780 0.2937
Table VI. Cox's model factors for the risk of loco-regional recurrence
Variable β Standard error p – value Relative risk
T-stage 0,0012
T2 0.6953 0.4118 0.0914 2.0042
T3 1.4500 0.4096 0.0004 4.2630
T4 1.1184 0.4804 0.0199 3.0598
respiratory inefficiency - .1361 0.3208 0.6713 0.8727
smoking (cigarettes/day * years) 0.1882
(0, 580] -.5280 0.3473 0.1284 0.5898
(580, 875] 0.0517 0.2862 0.8567 1.0530
>875 -.4739 0.3367 0.1593 0.6226
Concomitant boost 0.2888 0.2409 0.2305 1.3348
Table VII. Early reactions
N (%)
372 (100%)
Pain at swallowing 237 (69%)
missing 30
Need for analgesics
local 32 (11%)
general 43 (15%)
narcotic 15 (5%)
missing 80
Muccositis
patchy 146 (44%)
confluent 158 (48%)
missing 40
Dysphagia
light 145 (43%)
severe 58 (17%)
missing 40
Skin erythrema 169 (92%)
missing 188
Dry desquamation 196 (82%)
missing 132
Moist desquamation 73 (41%)
missing 194
Table VIIIa. Late reactions
N (%)
Skin teleangiectasiae 
no 231 (92.4)
(0, 1] cm 13 (5.2)
[1, 4) cm 5 (2.0)
> 4cm 1 (0.4)
missing 122
Skin oedema 
no 211 (85.1)
light 22 (8.9)
medium 12 (4.8)
severe 3 (1.2)
missing 124
Skin fibrosis
no 216 (86.4)
light 25 (10.0)
medium 9 (3.6)
missing 122
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was found to be the only significant risk factor of loco-re-
gional recurrence (Table IV). Respiratory insufficiency
and cigarette smoking did not influence loco-regional
outcomes.
Pain on swallowing and confluent mucositis were
the most frequent early reactions.
Medical remarks and considerations
In retrospective studies statistical analysis is usually per-
formed following the typical outline of estimating the tre-
atment outcomes and prognostic factors. This is the fra-
mework which provides the answers to the most essential
questions and facilitates the comparisons with other stu-
dies. However, apart from such fundamental statistical
estimations, there are several problems which require
further attention and interpretation [6-12].
About 45% of patients qualified for treatment by
radiotherapist – and – ENT surgeon team were in ad-
vanced stages of the disease (T3-T4), and, in 27 % of ca-
ses, presented cervical lymph node metastases. The inten-
tion of such policy was to preserve the larynx, while radi-
cal surgical treatment was considered only as salvage
surgery in patients either not cured, or with recurrent
cancer. In our material only 29% of these recurrence pa-
tients were operated. In 71% of such cases surgery was
not performed for a number of reasons, such as lack of
patient consent, highly advanced stage of disease after
a very long time of awaiting admission, etc. It must also be
kept in mind that in a number of uncured patients tu-
mour growth was much more rapid after radiotherapy.
In our opinion better collaboration between radiotherapi-
sts and surgeons provides a chance for considerable im-
provement of treatment outcomes.
The radiotherapists are chiefly interested in local
curability, estimated at least three years after treatment.
Local control is the fundamental criterion of treatment ef-
ficacy, while in the studies on the outcomes of radiothera-
py statistical analysis must give a clear and univocal an-
swer to this question. Complete regression (CR), often
applied in clinical elaboration, is very important in evalu-
ating the efficiency of chemotherapy, where local curabi-
lity is seldom the subject of the main interest and treat-
ment efficicacy is usually presented as overall survival.
However, CR estimation can give quite reliable informa-
tion and allow to compare the significance of the studied
clinical factors. This first estimation of outcome is also im-
portant because a majority of local failures are diagnosed
at that moment. Patients with recurrence should be imme-
diately referred for surgery. Another reason for follow
up examinations to be held immediately after the end of
treatment is to estimate the intensity of postirradiation re-
actions – an indicator of treatment tolerance.
The survival curves (Figure 1, 2) come down steeply
not only during the first two years, but also three and
more years after treatment completion. When confronted
with the curve illustrating the local regional outcomes,
it may indicates that after three years mortality is
not brought on by primary cancer, but rather by other
causes, such as distant metastases, second primary can-
cer – chiefly of the lung – or other diseases. The pro-
blem of this "over-mortality" is the subject of a separate
study.
The influence of overall treatment time on local con-
trol in head and neck cancer was the subject of many pa-
pers [6, 12, 13]. The prolongation of total treatment time
is considered to be one of the most important factors ne-
gatively influencing treatment outcomes. This problem
is the subject of separate study.
The local regional outcomes of treatment – 62% of
cure in early cases and 36% in patients with stage T3-T4 –
are less satisfactory then expected, especially in non-ad-
vanced cases. The limited number of serious reactions
and late complications suggests the possibility of incre-
asing the total dose or shortening the total time of treat-
ment within the limits of admissible morbidity.
Table VIIIb. Late reactions
N (%)
Mucosal ulceration 
no 242 (96.0)
yes 10 (4.0)
missing 120
Mucosal teleangiectasiae
no 237 (95.6)
(0, 1] cm 8 (3.2)
[1, 4) cm 2 (0.8)
> 4cm 1 (0.4)
missing 124
Deep mucosal necrosis
no 246 (96.9)
yes 8 (3.1)
missing 118
Dysphagia
no 228 (88.7)
light 15 (5.8)
medium 9 (3.5)
severe 5 (1.9)
missing 115
Dryness
no 206 (83.7)
light 21 (8.5)
medium 16 (6.5)
severe 3 (1.2)
missing 126
Oedema
no 200 (77.2)
yes 59 (22.8)
missing 113
Chondritis
no 243 (94.9)
yes 13 (5.1)
missing 116
Chondronecrosis
no 246 (96.9)
yes 8 (3.1)
missing 118
Bone necrosis
no 255 (97.7)
yes 6 (2.3)
missing 111
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Literature data indicates worse radiotherapy outco-
mes in patients not refraining from tobacco smoking du-
ring the course of irradiation. This observation was not
proven by our study material.
Prof. Andrzej Hliniak M.D., Ph.D.
2nd Department of Radiation Oncology
The Maria Sklodowska-Curie Memorial Cancer Center
and Institute of Oncology
Roentgena 5, 02-781 Warsaw, Poland
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